Resilience Biotechnologies: Why Are Investors Looking For This Stock?

May 19, 2021 12:34 PM EDT | By Anuj
 Resilience Biotechnologies: Why Are Investors Looking For This Stock?
Image source: Olena Yakobchuk,Shutterstock

On Wednesday, May 19, the Canadian government announced a C$ 200-million funding to Ontario-based Resilience Biotechnologies Inc for the upgradation of its mRNA vaccine plant that can help develop millions of shots.

Innovation Minister François-Philippe Champagne stated that the fund allocation is to develop an existing facility to offer "native solutions such as mRNA vaccines and treatments for pandemics."

Mr Champagne further stated the investment will increase Resilience's production capacity to churn out vaccines and therapeutics, such as mRNA jabs, which are being used to combat COVID-19 infections. He has also accepted that the country faced difficulties bringing big vaccine makers to Canada amid the COVID-19 pandemic due to limited production and packaging capacity to execute a mass production of shots.

In the light of this announcement, investors seem to be looking for the stocks of Resilience Biotechnologies.

However, with Resilience being a private firm, its shares are not listed on stock exchanges.

Copyright ©Kalkine Media 2020

The Canadian government has said that the expansion will also provide some 500 permanent jobs and 50 co-op positions for students once the plant gets ready in 2024.

Resilience plans to expand the site by nearly 55,000 square feet, which will allow it to produce between 112 million and 640 million shots of mRNA yearly. The Trudeau-led government is aiming to reduce Canada’s dependence on foreign vaccine manufacturers for future pandemics and this development will help in that plan.

A Glance At Resilience Biotechnologies

Resilience engages in drug manufacturing through a technology dedicated to expanding access to complex drugs and overseeing biopharma supply chains. Founded in 2020, the biotech firm builds high-tech sustainable network and end-to-end medicine production solutions.

Biopharmaceutical manufacturers are currently working at an accelerated pace on technological advancement that can help discoveries reach patients at a higher speed and scale.

For that, the government has awarded Resilience with this exclusive investment for its research and development (R&D) expansion. The company also invests in next-generation R&D to manufacture cell and gene therapies, vaccines, viral vectors, and proteins.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.